Evaluation de la prévention des hépatites non A, non B post-transfusionnelles en France

Degos, Françoise; Janot, C.; Fleurette, F; Durieux, Pierre

doi:10.4267/10608/4435

Med Sci (Paris)

1991

DOI: 10.4267/10608/4435

|View full text |Cite

Evaluation de la prévention des hépatites non A, non B post-transfusionnelles en France

Françoise Degos¹,

C. Janot²,

F Fleurette³

et al.

Abstract: Evalua tion de la prévention des hépatites non A, non 8 post-transfusionnelles en France Les hépatites non A, non B constituent un risque trans fu sionne! majeur puisque, en l'absence de tests de dépis mis n ° 7, uol. 7, septembre 91

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

1997

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Colin

Vergnon

Jullien³

et al. 1997

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

The current approach to screening for hepatitis C and non-A, non-B, non-C hepatitis in French blood transfusion centers involves a combination of a transaminase assay and tests for antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis C virus (anti-HCV). A decision-analysis model was used to assess the cost-effectiveness ratio of this approach compared to the former approach, which included only transaminase and anti-HBc screening. Cost data were collected by a questionnaire sent to 26 centers throughout France. The average costs of diagnostic kits, equipment, staff, and administration were calculated. Estimates of prevalence and sensitivity values came from the medical literature. The cost-effectiveness ratio was expressed in French francs per infected donor detected. A sensitivity analysis of the variables in the model was performed to estimate the validity of the cost-effectiveness ratio. For 100,000 donations the incremental cost of the current approach reached FrF 2,566,111 (about US $500,000), with a marginal effectiveness of 180 donations detected. The sensitivity analysis showed the effect of prevalence on the incremental cost-effectiveness ratio. Transfusion centers may change their screening approach in areas of high or low prevalence of hepatitis C in France.

show abstract

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Colin

Vergnon

Jullien³

et al. 1997

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

show abstract

Hépatite C en pratique transfusionnelle

Jullien

1995

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

European Acute Transfusion Hepatitis Interferon Study (EATHIS)

Jullien

Dejean

Janot

et al. 1992

Revue Française de Transfusion et d'Hémobiologie

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluation de la prévention des hépatites non A, non B post-transfusionnelles en France

Abstract: Evalua tion de la prévention des hépatites non A, non 8 post-transfusionnelles en France Les hépatites non A, non B constituent un risque trans fu sionne! majeur puisque, en l'absence de tests de dépis mis n ° 7, uol. 7, septembre 91

Cited by 4 publications

References 2 publications

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Hépatite C en pratique transfusionnelle

European Acute Transfusion Hepatitis Interferon Study (EATHIS)

Contact Info

Product

Resources

About